Cargando…
Genomic scars as biomarkers of homologous recombination deficiency and drug response in breast and ovarian cancers
Poly (ADP-ribose) polymerase (PARP) inhibitors and platinum-based chemotherapies have been found to be particularly effective in tumors that harbor deleterious germline or somatic mutations in the BRCA1 or BRCA2 genes, the products of which contribute to the conservative homologous recombination rep...
Autores principales: | Watkins, Johnathan A, Irshad, Sheeba, Grigoriadis, Anita, Tutt, Andrew NJ |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053155/ https://www.ncbi.nlm.nih.gov/pubmed/25093514 http://dx.doi.org/10.1186/bcr3670 |
Ejemplares similares
-
Relationship between homologous recombination deficiency and clinical features of breast cancer based on genomic scar score()
por: Feng, Cong, et al.
Publicado: (2023) -
Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision Oncology
por: van der Wiel, Alexander M. A., et al.
Publicado: (2022) -
Biomarkers for Homologous Recombination Deficiency in Cancer
por: Wagener-Ryczek, Svenja, et al.
Publicado: (2021) -
Normalized LST Is an Efficient Biomarker for Homologous Recombination Deficiency and Olaparib Response in Ovarian Carcinoma
por: Christinat, Yann, et al.
Publicado: (2023) -
Pan-cancer analysis of genomic scar signatures associated with homologous recombination deficiency suggests novel indications for existing cancer drugs
por: Marquard, Andrea M, et al.
Publicado: (2015)